Mr. Jeffrey J. Stewart

Biotech research and development (R&D) may be risky, but in his new policy brief, "Biotechnology Valuations for the 21st Century," Jeffrey Stewart, President of Clinical Capital Group, explains in simple detail how to quantify that risk more precisely than in the past.According to Stewart, past uncertainty associated with biologic manufacturing has largely been dispelled enabling the value of biotech R&D projects to be estimated by incorporating clinical-trial success rates into a traditional discounted cash flow analysis.In this policy brief, Stewart presents risk-adjusted net present value as a straightforward method of determining the value of biotech R&D assets.For more details, click here

Milken Institute Review Second Quarter 2002The latest issue of our quarterly journal looks at ways to solve Argentina's economic woes, the Sept. 11 Victim Compensation Fund, the impact of biotechnology on America's health-care system, California's experiment with electricity deregulation, and much more.More....

Jeffrey J. Stewart, MA
...
Jeffrey J. Stewart, MA

Jeffrey J. Stewart prices biotechnology assets as the President of Clinical Capital Group and a founding partner of SmallCap BioPharma.Mr. Stewart has published his methodology over the last 18 months in the leading biotech journal, Nature Biotechnology and as a Milken Institute Policy Brief.
...
In addition to helming Clinical Capital Group, Mr. Stewart also manages a portion of endowment funds for Notre Dame University where he is currently pursuing an MBA degree.